- 18 conditions analyzed: Faex Health's AI stool screening platform now investigates 18 gastrointestinal and related health conditions.
- 50,000 active users: The company reports 50,000 active users as of November 2026.
- Investigational only: The technology lacks FDA clearance and is not intended for diagnostic purposes.
Experts remain skeptical about the platform's ability to diagnose specific pathogens like H. pylori and Ebola from stool photographs, emphasizing the need for rigorous clinical validation and regulatory oversight.
AI Stool Screening: Medical Breakthrough or Silicon Valley Overreach?
NEW YORK, NY – November 20, 2026 — The future of preventative medicine might just be sitting in your toilet bowl. Or, at least, that is the audacious premise behind Faex Health, a digital health startup that has developed artificial intelligence tools to analyze human stool via smartphone photography. Unveiled today during HITLAB’s Center for AI Testing and Evidence program, the company announced the addition of Ebola virus disease and Helicobacter pylori (H. pylori) to its investigational pre-screening platform.
The expansion brings the company’s internally validated panel to 18 gastrointestinal and related health conditions. Using a standard smartphone camera, the platform's computer vision analyzes visual characteristics—including color, consistency, texture, blood, mucus, and other anomalies—to generate preliminary health indicators.
Yet, as consumer computer vision pushes further into the realm of complex diagnostics, the announcement highlights a growing tension in the digital health sector. Can an algorithm truly identify a microscopic pathogen from a surface-level photograph, or is this the latest example of Silicon Valley overpromising on the capabilities of artificial intelligence?
A Shot in the Dark? The Scientific Skepticism
The claim that a smartphone camera could identify markers for H. pylori and Ebola has been met with intense skepticism from the medical community.
H. pylori is a microscopic bacterium that colonizes the stomach lining, affecting roughly half the global population and serving as a primary risk factor for peptic ulcers and gastric cancer. Standard diagnostic methods include urea breath tests, stool antigen tests, or endoscopic biopsies. Similarly, Ebola virus disease is a severe, often fatal systemic illness whose confirmatory diagnosis requires specialized laboratory testing, typically reverse transcription polymerase chain reaction (RT-PCR) to detect viral RNA.
While both conditions can cause gastrointestinal distress, clinical microbiologists are quick to point out that surface-level visual changes in stool are inherently non-specific.
"You cannot diagnose a microscopic bacterial colonization or a systemic viral hemorrhagic fever from a macroscopic photograph," noted one infectious disease specialist familiar with digital diagnostics. "While AI might accurately categorize stool consistency against the Bristol Stool Scale, correlating those broad visual markers with specific pathogens without biochemical or microscopic detection is scientifically implausible. The risk of false reassurance or unnecessary panic is incredibly high."
Faex Health carefully navigates this skepticism by explicitly stating that its technology is investigational, lacks U.S. Food and Drug Administration (FDA) clearance, and is not intended to diagnose diseases or replace established laboratory testing. Both the H. pylori and Ebola indications have only undergone internal validation using proprietary datasets and have not yet entered clinical trials or been subjected to peer review.
Democratizing Diagnostics in the Triage Gap
Despite the scientific hurdles, the global health implications of a non-invasive, instantly accessible triage tool cannot be entirely dismissed. In resource-constrained environments where PCR machines, specialized reagents, and trained laboratory personnel are scarce, public health officials face significant delays in identifying outbreak clusters.
Faex Health Co-Founder and CEO Landon Nattrass positions the platform as a bridge across this exact divide.
"From one of the world's most widespread bacterial infections to one of its most dangerous viral diseases, H. pylori and Ebola illustrate the extraordinary range of public health challenges Faex Health is working to address," Nattrass said during the virtual HITLAB presentation. "By expanding our investigational platform to include both conditions, we are exploring how technology people already carry in their pockets could help bridge gaps in health monitoring, particularly where access to traditional testing is limited."
If the AI can be trained to recognize the specific, severe visual anomalies associated with gastrointestinal distress in Ebola patients—such as distinct patterns of blood and mucus—it could theoretically serve as an early warning mechanism. In an outbreak environment, a red flag from a smartphone app might not confirm Ebola, but it could trigger immediate isolation protocols and prioritize that individual for scarce RT-PCR testing.
Navigating the Regulatory Tightrope
The boundary between a helpful "pre-screening indicator" and a regulated medical device is notoriously thin. The FDA regulates Software as a Medical Device (SaMD) based on its intended use and the risk posed to patients if the software fails.
By labeling its platform as an "investigational pre-screening tool" meant for "health awareness," Faex Health is attempting to operate outside the stringent requirements of Class II or Class III medical devices. However, regulatory attorneys warn that tools targeting high-risk pathogens often attract regulatory scrutiny regardless of their marketing language. If an algorithm suggests the potential presence of Ebola and a clinician or patient alters their behavior based on that output, the software is effectively driving a medical decision.
To build clinical credibility, the company is pursuing more visually plausible applications of its technology. Faex Health is currently serving as the technology collaborator in the FECAL-AI clinical trial at Hospital Dr. Sótero del Río in Chile. That study is evaluating the platform’s ability to detect signals associated with colorectal cancer risk against conventional fecal immunochemical testing (FIT). Detecting microscopic or macroscopic blood associated with colorectal neoplasia is a far more established visual metric than identifying viral pathogens. Additionally, the company is in the early planning stages of a large-scale colorectal cancer screening study in the United Kingdom involving the National Health Service (NHS).
The Continuous Gut and the Business of Excrement
While the scientific debate over Ebola and H. pylori detection will likely rage on, Faex Health has already found a lucrative foothold in the commercial market. The company reports four signed agreements representing approximately 150,000 covered lives, with 50,000 active users as of this month.
This commercial traction underscores a massive shift in how the healthcare industry views longitudinal data. Rather than waiting for patients to present with symptoms at a clinic, digital health companies are monetizing continuous, passive daily surveillance. Faex Health sells its platform not as a diagnostic replacement, but as a wellness and engagement benefit to self-insured employers and health plans.
For benefits managers, the value proposition lies in preventative engagement. If an employee uses an app to track their digestive health and the AI flags a persistent anomaly, that employee might seek medical care months before a minor issue becomes a catastrophic, high-cost medical claim. In exchange, the startup gains access to a recurring revenue stream and a rapidly expanding dataset of user-generated imagery, which is critical for training its machine-learning models.
"Your gut produces information about your health every day, yet most of that information is never captured or evaluated," Nattrass explained. "Our vision is to make monitoring those changes as routine as checking your heart rate or tracking your sleep."
As Faex Health prepares to present its broader vision at the HITLAB Innovators Summit in December, the company stands at a fascinating crossroads. It has successfully commercialized the taboo subject of bowel movements into a scalable digital wellness product. Yet, as it pushes its AI into the high-stakes arenas of infectious disease and global pandemics, it will have to prove that its algorithms are seeing something the rest of the medical community cannot.
Topics & Related
Medical AI
📝 This article is still being updated
Are you a relevant expert who could contribute your opinion or insights to this article? We'd love to hear from you. We will give you full credit for your contribution.
Contribute Your Expertise →